Growth in this market is attributed to the growing drug & alcohol consumption and the enforcement of stringent laws mandating drug & alcohol testing, rising regulatory approvals for drug screening products & services
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773
Drug screening tests help analyze and diagnose biological samples such as blood, hair, and urine, and help detect the presence of drugs of abuse or its metabolites in a person's body.
Based on the product, the drug screening market is segmented into analytical instruments, rapid testing devices, and consumables. the analytical segment is expected to dominate the market with a share of 53.0%.
By sample type, drug screening market is segmented into urine, breath, oral fluid, hair, and other samples. Among these, the urine sample segment is expected to account for the largest share of 61.5%
Based on service and product, the drug screening market is segmented into services and products. The services segment accounted for the largest share of 57.4% of the drug screening market.
North America is expected to dominate the market with a share of 48.2%, followed by Europe. The large share of this geographical segment is attributed to factors such as growing consumption of illicit drugs, the availability of government funding to curb drug abuse, laws supporting drug screening, the growing burden of accidents due to alcohol impairment, and the presence of key players in the region are driving the growth of the drug screening market in this region.
Key Market Players
The drug screening market is highly competitive with the presence of several small and big players. Some of the players offering products for drug screening market include Abbott Laboratories (US), Thermo Fisher Scientific (US), Quest Diagnostics (US), Alfa Scientific Designs (US), Roche (Switzerland), OraSure Technologies (US), MPD Inc. (US), and Shimadzu (Japan).
Expected Revenue Growth:
The global drug screening market is projected to reach USD 11.6 billion by 2026, from USD 5.3 billion in 2021, at a CAGR of 16.8% during the forecast period.
LabCorp (US): LabCorp is a leading player in the US drug screening services market. The company’s leading position is attributed to its wide drug testing portfolio, including over 4,800 tests.